Table 2 Minor reported AEs from reviewed studies

GI disturbances

Rondanelli et al. 2010 [40]

6/22 (27.3%)

5/22 (22.7%)

Van de Rest et al. 2009 [36–39]^a

High dose: 10/96 (10.4%)

12/106 (11.3%)

Low dose: 9/100 (9%)

Thies et al. 2001 [31, 32]

1/8 (12.5%)

-

Fakhrzadeh et al. 2010 [43]

2/62 (3%)

1/62 (1.5%)

Holguin et al. 2005 [44]

14/26 (53.8%)

6/26 (23.1%)

Headache

Rondanelli et al. 2010 [40]

-

1/24 (4%)

Skin irritation

Gruenwald et al. 2009 [42]

2/90 (2%)

-

Van de Rest et al. 2009 [32–35]^a

-

1/106 (0.9%)

Vertigo

Fakhrzadeh et al. 2010 [43]

1/62 (1.5%)

-

Malaise

Fakhrzadeh et al. 2010 [43]

1/62 (1.5%)

-

Van de Rest et al. 2009 [32–35]^a

Low dose: 1/100 (1%)

-

Weight gain

Van de Rest et al. 2009 [32–35]^a

High dose: 1/96 (1%)

-

Polyurination

Van de Rest et al. 2009 [32–35]^a

High dose: 1/96 (1%)

-

Restlessness

Van de Rest et al. 2009 [32–35]^a

High dose: 1/96 (1%)

-

Blurred vision

Van de Rest et al. 2009 [32–35]^a

Low dose: 1/100 (1%)

1/106 (0.9%)

Sore throat

Van de Rest et al. 2009 [32–35]^a

Low dose: 1/100 (1%)

-

Skeletal muscle pain

Van de Rest et al. 2009 [32–35]^a

Low dose: 1/100 (1%)

1/106 (0.9%)